Related Experiment Video
Updated: Apr 18, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Catalase C-262T polymorphism and risk of prostate cancer: evidence from meta-analysis
Jieping Hu1, Fupeng Feng1, Shimiao Zhu1
1Department of Urology, The 2nd Hospital of Tianjin Medical University, Tianjin Institute of Urology, National Key Clinical Specialty of Urology, Tianjin Key Lab of Urology, 23 Pingjiang Road, Hexi District, Tianjin 300211, China.
Abstract:
Catalase is an important endogenous antioxidant enzyme that detoxifies hydrogen peroxide to oxygen and water, thus limiting the deleterious effects of reactive oxygen species. Several studies investigated the role of the Catalase (CAT) C-262T gene polymorphism on the risk of prostate cancer (PCa), but get conflicting results. We performed a meta-analysis based on five studies, to determine whether Catalase C-262T polymorphism contributes to the risk of prostate cancer using odds ratios (OR) with 95% confidence intervals (CI). On the whole, our evidence indicates that CAT C-262T polymorphism significantly increases PCa risk in the allele comparison model (OR=1.094, 95% CI=1.015-1.178, P=0.018). In the stratified analysis by ethnicity, the same results are found among Caucasians (allele model, OR=1.090, 95% CI=1.009-1.177, P=0.028, dominant model, OR=1.108, 95% CI=1.023-1.201, P=0.012, recessive model, OR=1.379, 95% CI=1.158-1.641, P=0.000, homozygous model, OR=1.429, 95% CI=1.196-1.707, P=0.000, and heterozygote model, OR=1.224, 95% CI=1.020-1.469, P=0.030). In conclusion, this meta-analysis suggests a positive correlation between Catalase C-262T polymorphism and the development of PCa.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Single Nucleotide Polymorphisms-SNPs
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Ras Gene
Ras is a...

